| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 12,551 | 31,496 | ||
| Marketable debt securities | 120,119 | 90,720 | ||
| Prepaid expenses and other current assets | 2,974 | 2,875 | ||
| Total current assets | 135,644 | 125,091 | ||
| Restricted cash, non-current | 745 | 745 | ||
| Marketable debt securities, non-current | 957 | 23,392 | ||
| Property and equipment, net | 828 | 912 | ||
| Operating lease right-of-use asset | 3,452 | 3,725 | ||
| Other assets | 3,010 | 3,068 | ||
| Total assets | 144,636 | 156,933 | ||
| Accounts payable | 4,504 | 5,299 | ||
| Accrued expenses and other current liabilities | 4,185 | 3,263 | ||
| Operating lease liability | 1,220 | 1,199 | ||
| Total current liabilities | 9,909 | 9,761 | ||
| Operating lease liability, non-current | 2,436 | 2,749 | ||
| Total liabilities | 12,345 | 12,510 | ||
| Common stock, 0.001 par value, authorized 100,000,000 shares common stock, 38,587,260 and 35,044,772 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 39 | 39 | ||
| Additional paid-in capital | 417,221 | 416,161 | ||
| Accumulated deficit | -285,112 | -271,854 | ||
| Accumulated other comprehensive income (loss) | 143 | 77 | ||
| Total stockholders equity | 132,291 | 144,423 | ||
| Total liabilities and stockholders equity | 144,636 | 156,933 | ||
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)